Dr. Carey Anders on Treating Brain Metastases in Breast Cancer

Publication
Video
Special ReportsBreast Cancer (Issue 2)
Volume 1
Issue 2

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

Articles in this issue
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Related Videos
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content
Shift to Value-Based Care Brings New Desires for EHR Capabilities

Shift to Value-Based Care Brings New Desires for EHR Capabilities

April 18th 2024
Article

A survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer

Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer

April 18th 2024
Article

During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.

Read More

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia

April 17th 2024
Article

During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.

Read More

Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

April 16th 2024
Article

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

Read More